protein

Biotinylated Human EGFR vIII (C-6His-Avi)

CY02

20 ug;100 ug

Biotinylated Human EGFR vIII (C-6His-Avi)

protein

NP_001333870

20 ug;100 ug

288

CY02-20ug

20ug;100ug

Biotinylated Recombinant Human Epidermal Growth Factor Receptor/Receptor Tyrosine Protein KinaseErbB1 is produced by our Mammalian expression system and the target gene encoding Leu25-Ser378 is expressed with a 6His, Avi tag at the C-terminus.

Human Cells

The EGFR subfamily of receptor tyrosine kinases is composed of EGFR, ErbB2, ErbB3 and ErbB4. The EGFR shares 43% - 44% aa sequence identity with the ECD of human EGFR subfamily. All these family members are type I transmembrane glycoproteins with an extracellular ligand binding domain. The extracellular ligand binding domain is containing two cysteine-rich domains separated by a spacer region and a cytoplasmic domain containing a membrane-proximal tyrosine kinase domain. Ligand binding could induce EGFR homodimerization and heterodimerization with ErbB2, resulting in cell signaling, heterodimerization tyrosine phosphorylation and kinase activation. It can bind EGF, amphiregulin, TGF-alpha, betacellulin, epiregulin, HB-EGF, epigen, and so on. Its signaling regulates multiple biological functions including cell proliferation, differentiation, motility, and apoptosis. EGFR can also be recruited to form heterodimers with the ligand-activated ErbB3 or ErbB4. EGFR is overexpressed in different tumors. Several anti-cancer drugs use EGFR as target.

Less than 0.1 ng/ug (1 EU/ug)

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Ambient

Epidermal growth factor receptor; EGFR; Proto-oncogene c-ErbB-1; Receptortyrosine-protein kinase erbB-1; EGFR